SCHEMBL375596

SCHEMBL375596

O=c1cccc2ccccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.47
ALOX15 P16050 1/20 0.40
POLB P06746 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.36
CHEK1 O14757 1/20 0.36
LIMK1 P53667 1/20 0.36
MAPK14 Q16539 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GLA P06280 3/20 0.34
GAA P10253 3/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9900893 0.92 ADORA3 (0.43) ADORA3ALOX15POLBNPSR1KDM4E
SCHEMBL3714621 0.73 KDM4E (0.44) ADORA3ALOX15POLBKDM4EALDH1A1
SCHEMBL18148022 0.72 MAPT (0.45) ADORA3POLBKDM4EALDH1A1MAPT
SCHEMBL19533508 0.72 KDM4E (0.44) KDM4EALDH1A1MAPTL3MBTL1GAA
SCHEMBL3464453 0.72
SCHEMBL25271465 0.72 MGLL (0.36) ALDH1A1L3MBTL1GAAHSP90AA1
SCHEMBL16376209 0.72 ADORA3 (0.36) ADORA3ALOX15POLBNPSR1KDM4E
SCHEMBL18161339 0.70 MAPT (0.49) ADORA3KDM4EALDH1A1MAPTCHEK1
SCHEMBL277389 0.70 ALOX15 (0.40) ADORA3ALOX15POLBKDM4EALDH1A1
SCHEMBL13112245 0.70 ALOX15 (0.40) ADORA3ALOX15POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3802549-B1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION HOFFMANN LA ROCHE (CH) 2023-03-01 EP claimed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP claimed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO claimed
US-10155021-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2018-12-18 US claimed
EP-2670410-B1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2017-12-20 EP claimed
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-08-17 US claimed
US-20170106045-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-04-20 US claimed
US-9403818-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2016-08-02 US claimed
EP-2670410-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Evolva SA (CH) 2013-12-11 EP claimed
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2013-09-26 US claimed
EP-1064284-B1 HYPNOTIC BETA-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS MACEF (FR) 2002-03-27 EP claimed
EP-1064284-A1 HYPNOTIC BETA-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS MACEF (FR) 2001-01-03 EP claimed
WO-1999047521-A1 HYPNOTIC β-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS MACEF (FR) 1999-09-23 WO claimed
EP-0309260-B1 4H-QUINOLIZIN-4-ONE COMPOUNDS EXHIBITING THERAPEUTIC ACTIVITIES Kissei Pharmaceutical Co., Ltd. (JP) 1992-01-15 EP claimed
US-4935425-A TREATMENT OF ALLERGIC ASTHMA, RHINITIS, DERMATITIS AND HYPERSENSITIVENESS KISSEI PHARMACEUTICAL CO., LTD. (JP) 1990-06-19 US claimed
US-4904657-A 4H-quinolizin-4-one compounds exhibiting therapeutic activities KISSEI PHARMACEUTICAL CO., LTD. (JP) 1990-02-27 US claimed
US-4877795-A 4H-quinolizin-4-one compounds useful for the treatment of allergic bronchial asthma, allergic rhinitis atropic dermatitis and the like KISSEI PHARMACEUTICAL CO., LTD. (JP) 1989-10-31 US claimed
EP-0317295-A2 4H-quinolizin-4-one compounds and pharmaceutical compositions containing them Kissei Pharmaceutical Co., Ltd. (JP) 1989-05-24 EP claimed
EP-0309260-A1 4H-Quinolizin-4-one compounds exhibiting therapeutic activities Kissei Pharmaceutical Co., Ltd. (JP) 1989-03-29 EP claimed
EP-0277755-A1 4H-quinolizin-4-one compounds exhibiting therapeutic activities Kissei Pharmaceutical Co. Ltd. (JP) 1988-08-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10155021-B2 Antimicrobial 4-oxoquinolizines DCAF15, CUL4A, CUL4B ADORA3 4484/4885ALOX15 1283/4885POLB 496/4885
US-20170106045-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B ADORA3 4499/4885ALOX15 1270/4885POLB 446/4885
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B ADORA3 4499/4885ALOX15 1270/4885POLB 446/4885
US-20130252882-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B ADORA3 4499/4885ALOX15 1270/4885POLB 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.